RS BioTherapeutics
RS BioTherapeutics is dedicated to developing life-changing medicines for diseases characterized by pulmonary inflammation. Their first investigational compound, RSBT-001, is a first-in-class, steroid-free therapeutic targeting respiratory diseases such as COPD, Idiopathic Pulmonary Fibrosis, Pulmonary Arterial Hypertension, and others. The company aims to file an IND for RSBT-001 in 2026 and is actively engaged in research, collaborations, and advancing cannabinoid-based therapies.
Industries
Nr. of Employees
small (1-50)
RS BioTherapeutics
Products
Investigational semi-synthetic cannabidiolic acid complex (nebulized inhalation formulation)
An investigational, steroid-free, multi-targeted immune modulator formulated for nebulized pulmonary delivery to treat diseases characterized by pulmonary inflammation; development targeted initially to COPD and idiopathic pulmonary fibrosis with IND planning.
Investigational semi-synthetic cannabidiolic acid complex (nebulized inhalation formulation)
An investigational, steroid-free, multi-targeted immune modulator formulated for nebulized pulmonary delivery to treat diseases characterized by pulmonary inflammation; development targeted initially to COPD and idiopathic pulmonary fibrosis with IND planning.
Services
Collaborative research agreements with academic, government, and industry partners to evaluate therapeutic candidates in preclinical and translational studies.
Design and execution oversight of in vivo and ex vivo preclinical studies with integrated biomarker endpoints to evaluate anti-inflammatory and anti-fibrotic activity.
Breeding and protection of plant cultivars intended to serve as standardized botanical raw materials for therapeutic programs.
Coordination with contract development and manufacturing organizations to perform product characterization, analytical testing, and support IND-enabling CMC activities.
Collaborative research agreements with academic, government, and industry partners to evaluate therapeutic candidates in preclinical and translational studies.
Design and execution oversight of in vivo and ex vivo preclinical studies with integrated biomarker endpoints to evaluate anti-inflammatory and anti-fibrotic activity.
Breeding and protection of plant cultivars intended to serve as standardized botanical raw materials for therapeutic programs.
Coordination with contract development and manufacturing organizations to perform product characterization, analytical testing, and support IND-enabling CMC activities.
Expertise Areas
- Pulmonary drug development
- Cannabinoid pharmacology and semi-synthetic modification
- Inhalation and nebulized formulation development
- Preclinical translational models for lung disease
Key Technologies
- Semi-synthetic cannabinoid chemistry
- Metal-coordination chemistry for small molecules
- Nebulized inhalation drug delivery
- Precision-cut lung slice (PCLuS) ex vivo platform
News & Updates
RS BioTherapeutics will present at the Respiratory Innovation Summit in San Diego, CA, on May 17-18, 2024, showcasing their science behind RSBT-001 for lung diseases.
RS BioTherapeutics will participate in the ATS 2024 in San Diego, CA, on May 17-22, 2024, highlighting their first-in-class, steroid-free agent RSBT-001 for lung diseases.
The company’s submission was selected for a poster presentation at the ATS 2024 Respiratory Innovation Summit, uniting global leaders in lung disease research.
RSBT-001 demonstrated significant reduction of inflammatory biomarkers and mediators of fibrosis in human lung tissue, supporting its potential as a treatment for lung diseases.
RS BioTherapeutics will present at the Respiratory Innovation Summit in San Diego, CA, on May 17-18, 2024, showcasing their science behind RSBT-001 for lung diseases.
RS BioTherapeutics will participate in the ATS 2024 in San Diego, CA, on May 17-22, 2024, highlighting their first-in-class, steroid-free agent RSBT-001 for lung diseases.
The company’s submission was selected for a poster presentation at the ATS 2024 Respiratory Innovation Summit, uniting global leaders in lung disease research.
RSBT-001 demonstrated significant reduction of inflammatory biomarkers and mediators of fibrosis in human lung tissue, supporting its potential as a treatment for lung diseases.